Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: J Subst Abuse Treat. 2019 Aug 17;106:97–106. doi: 10.1016/j.jsat.2019.08.007

Table 2.

Past 6 month receipt of alcohol treatment medications at baseline and follow-up by treatment group

Medication, n (%) Integrated Stepped Alcohol Treatment (n=46) Treatment as Usual (n=49) p value
Any alcohol treatment medicationa
 Baseline 6 (12.2) 3 (6.5) 0.49
 Week 24 8 (16.3) 3 (6.5) 0.14
 Week 52 5 (10.2) 4 (8.7) 1.0
Disulfiram
 Baseline 0 (0) 0 (0) NA
 Week 24 0 (0) 0 (0) NA
 Week 52 0 (0) 0 (0) NA
Acamprosate
 Baseline 0 (0) 0 (0) NA
 Week 24 0 (0) 0 (0) NA
 Week 52 0 (0) 0 (0) NA
Naltrexone
 Baseline 0 (0) 0 (0) NA
 Week 24 2 (4.1) 0 (0) 0.50
 Week 52 0 (0) 0 (0) NA
Topiramate
 Baseline 0 (0) 0 (0) NA
 Week 24 0 (0) 0 (0) NA
 Week 52 0 (0) 1 (2.2) 0.48
Baclofen
 Baseline 0 (0) 1 (2.2) 0.48
 Week 24 0 (0) 1 (2.2) 0.48
 Week 52 0 (0) 2 (4.4) 0.23
Gabapentin
 Baseline 6 (12.2) 3 (6.5) 0.49
 Week 24 7 (14.3) 3 (6.5) 0.32
 Week 52 5 (10.2) 2 (4.4) 0.44
a

. Based on receipt of disulfiram, acamprosate, naltrexone, topiramate, baclofen and/or gabapentin.